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The importance of pediatric genomics studies
There are a number of compelling reasons why pediatric 
populations  should  be  preferentially  studied  to  under­
stand the genomic basis of disease. First, many forms of 
adult disease have genetic etiologies that were discovered 
in  pediatric  studies  (for  example,  cardiomyopathies, 
several causes of infertility and colorectal cancer) where 
the more penetrant or homozygous mutations, clinically 
presenting in early childhood, made the genetic patho­
genesis much clearer than in adult disease. Second, being 
able  to  detect  the  genetic  antecedents  of  adult  disease 
best allows us to study how the disease develops on the 
way  to  adulthood  and,  just  as  importantly,  gives  the 
longest possible lead time for the implementation of the 
most cost­effective primary prevention (for example, use 
of  angiotensin  converting  enzyme  inhibitors  to  reduce 
the cardiac manifestations of Marfan syndrome if given 
in  childhood).  Third,  the  individual  variation  due  to 
environmental  exposures,  whether  it  be  diet,  drugs  or 
other habits, is by definition relatively small compared 
with that of adults who have had an order of magnitude 
more  exposure  to  the  environment.  Consequently,  the 
case  could  be  made  that  a  greater  fraction  of  patho­
physiological variability in children can be attributable to 
inherited traits (although one could make several oppos­
ing arguments, including the increased suscepti  bility of 
children to certain environmental insults). Last, and most 
importantly, children constitute a population with distinct 
physiology and disease risks and there is no substitute for 
pediatric genomics studies in order to better understand 
and ultimately manage or treat these risks and diseases. 
So why is it that pediatric genomic studies form only a 
small fraction of the entire collection of genomic studies 
formed to date?
Challenges in pediatric genomics research
There is more here than just the usual underfunding of 
pediatric projects relative to adult projects, although this 
certainly may be an important factor [1]. In many ways 
the  barriers  mirror  some  of  those  that  cause  under­
representation  of  historically  under­represented  and 
underserved minorities in genetic studies as outlined by 
Francis Collins and colleagues [2]. One important con­
sideration is that it is just much harder to perform genetic 
studies with children. To start with, there is the matter of 
consent and assent. Children are not children forever and 
therefore  the  parental  consent  most  likely  has  to  be 
eventually  replaced  by  childhood  assent  and  then  full 
consent as they reach maturity [3]. This already imposes 
significantly  more  in  terms  of  overheads  for  consent 
management  than  those  incurred  by  adult  prospective 
studies.
Then there is the challenge of obtaining the biological 
sample. In the judgment of many parents, most children, 
and a few institutional review boards, the pain and small 
risks of venipuncture for blood samples outweigh poten­
tial benefits, particularly for healthy children. The alter­
na  tive (for example, obtaining saliva as a source of DNA) 
often  results  in  suboptimal  genomic  analyses  due  to 
difficulties in obtaining an adequate quantity of sample in 
young children.
In addition, most pediatric care is delivered in small 
practices, and much of this care and ancillary measure­
ments are not documented in the electronic health records 
that are mostly found in larger healthcare systems. This 
makes  identification  of  cases  and  controls  largely  an 
expensive and manual operation. Moreover, the transi­
tion  to  adulthood  almost  always  entails  a  change  in 
health  care provider and healthcare delivery system and 
therefore  a  discontinuity  in  record  keeping  (electronic 
and/or paper). This results in loss of follow­up informa­
tion  that  is  essential  for  genomic  studies  that  address 
long­term outcomes.
Perhaps  most  challenging  is  that  there  is  not  one 
population of children but many populations with truly 
distinct physiologies: neonates have dramatically differ­
ent ‘normal’ ranges (for example, for ionic and endocrine 
analytes) and physiologies (for example, relative depen­
dence on glucose as a primary metabolic fuel) compared 
with even a 1 month old. Early childhood, puberty and 
adolescence also constitute such different physio  logical  © 2010 BioMed Central Ltd
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considered in genomic studies to pale by comparison.
Overcoming the challenges
These barriers are not insurmountable and several steps 
can be taken now to address them. First, any pediatric 
research institution should implement a routine consent 
tracking system designed for children growing up through 
adulthood, and which allows for all the complexities of 
maturation  of  autonomy  and  changes  in  guardianship 
and family structure. Second, the chemistries for sample 
preparation  for  ‘next  generation’  sequencing  can  and 
likely  will  be  optimized  to  yield  high­quality  genomic 
data from much smaller samples of cellular material in 
saliva or easily brushed off skin. Perhaps even more so 
than  for  adult  studies,  every  opportunity  to  study  and 
measure children as they progress through the various 
states  of  development  has  to  be  fully  leveraged,  while 
maximizing the autonomy and privacy of the child and 
his/her family, by accelerating the adoption of pediatric 
electronic health records and the infrastructure required 
[4].  Finally,  the  transition  of  record  keeping  from 
pediatric  to  adult  care  must  be  addressed  whether  by 
mandate [5] or by implementation of national or region­
ally integrated health records or even by patient­driven 
solutions such as personally controlled health records [6]. 
With  regard  to  the  latter,  pediatricians  have  long 
implemented the paper­based equivalent of a personally 
controlled record (that is, a paper log of all immunizations 
and blood tests, and occasionally major anthropometric 
measures) and placed them in the possession of parents. 
However, these frequently misplaced paper records are 
increasingly  being  replaced  by  electronic  equivalents 
despite ongoing concerns regarding electronic access and 
health  literacy.  With  the  concurrent  growth  in  large 
institutional  and  national  biobanks,  there  is  an  oppor­
tunity  to  merge  integrated  health  records  with  the 
biomaterials in these biobanks [7] and thereby accelerate 
pediatric  genomic  studies.  The  same  institutions  and 
countries  are  also  well  positioned  to  set  the  standard 
internationally  for  both  the  information  technology 
practices  and  the  consenting  and  consent­tracking 
practices that are required for pediatric studies. Such an 
international  collaborative  effort  will  be  necessary  to 
achieve  sufficient  sample  sizes  of  at  least  100,000  for 
important pediatric quantitative traits.
Finally,  the  strategies  outlined  above  depend  on  a 
productive  professional  relationship  between  primary 
care  pediatricians  (who  will  be  providing  the  bulk  of 
clinical characterization) and genome­scale researchers. 
Successful incentive models whether financial or through 
academic attribution and advancement have been elusive 
in  the  face  of  ongoing  pediatrician  concern  regarding 
extra  work,  lack  of  resources,  lack  of  rewards  and 
recognition, difficulty in providing informed consent, and 
fear  of  losing  patients  [8].  My  own  intuition  is  that  a 
commitment on the part of researchers to interpret novel 
and pertinent genetic findings in a manner that can easily 
be shared with the patients to which the findings apply 
will create an added incentive [9] that will augment the 
currently tenuous bond between pediatrician, researcher 
and  patient  that  is  essential  to  pediatric  genomic 
research.
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